Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage...

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin...

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin...

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer...

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy...

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy...

Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the dangerous...

Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the dangerous...